Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

1
results for

"Chan Yiong Huak"

Article category

Keywords

Publication year

"Chan Yiong Huak"

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani
Clin Mol Hepatol 2023;29(1):135-145.
Published online September 5, 2022
DOI: https://doi.org/10.3350/cmh.2022.0181
Background/Aims
The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim to validate the performance of CSPH criteria to predict the risk of decompensation in an international real-world cohort of cACLD patients.
Methods
cACLD patients were stratified into three categories (CSPH excluded, grey zone, and CSPH). The risks of decompensation across different CSPH categories were estimated using competing risk regression for clustered data, with death and hepatocellular carcinoma as competing events. The performance of “treating definite CSPH” strategy to prevent decompensation using non-selective beta-blocker (NSBB) was compared against other strategies in decision curve analysis.
Results
One thousand one hundred fifty-nine cACLD patients (36.8% had CSPH) were included; 7.2% experienced decompensation over a median follow-up of 40 months. Non-invasive assessment of CSPH predicts a 5-fold higher risk of liver decompensation in cACLD patients (subdistribution hazard ratio, 5.5; 95% confidence interval, 4.0–7.4). “Probable CSPH” is suboptimal to predict decompensation risk in cACLD patients. CSPH exclusion criteria reliably exclude cACLD patients at risk of decompensation, regardless of etiology. Among the grey zone, the decompensation risk was negligible among viral-related cACLD, but was substantially higher among the non-viral cACLD group. Decision curve analysis showed that “treating definite CSPH” strategy is superior to “treating all varices” or “treating probable CSPH” strategy to prevent decompensation using NSBB.
Conclusions
Non-invasive assessment of CSPH may stratify decompensation risk and the need for NSBB in cACLD patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Advances in imaging—Elastography
    Elton Dajti, Adrian T. Huber, Giovanna Ferraioli, Annalisa Berzigotti
    Hepatology.2026; 84(3): 952.     CrossRef
  • Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(1): e58.     CrossRef
  • The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an inter
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(1): 403.     CrossRef
  • Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis
    Xin En Goh, May Xuan Goh, Vincent L. Chen, Guadalupe Garcia-Tsao, Juan G. Abraldes, Yu Jun Wong
    Clinical Gastroenterology and Hepatology.2026; 24(4): 911.     CrossRef
  • Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis
    Yu Jun Wong, Laurent Lam, Pierre-Antoine Soret, Sara Lemoinne, Bettina Hansen, Gideon Hirschfield, Aliya Gulamhusein, Ellina Lytvyak, Albert Pares, Ignasi Olivas, Maria-Carlota Londono, Sergio Rogriguez-Tajes, John E. Eaton, Karim T. Osman, Christoph Schr
    Journal of Hepatology.2026; 84(2): 275.     CrossRef
  • Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver disease
    Georg Kramer, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, Benedikt Silvester Hofer, Nina Dominik, Lukas Hartl, Michael Schwarz, Georg Semmler, Christian Sebesta, Paul Thöne, Sophia Geisselbrecht, Benjamin Maasoumy, Eduardo Alvarez, Martin Sebastian
    JHEP Reports.2026; 8(2): 101642.     CrossRef
  • The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease
    Laia Aceituno, Juan Bañares, Mònica Pons, Jesús Rivera-Esteban, Clara Sabiote, Calogero Cammà, Giacinta Ciancimino, Grazia Pennisi, Adele Tulone, Mang M. Ma, Xiangyu Liu, Timothy R. Watkins, Andrew N. Billin, Salvatore Petta, Juan M. Pericàs, Juan G. Abra
    Gastroenterology.2026; 170(2): 385.     CrossRef
  • Editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
    Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang, Yu Jun Wong
    Clinical and Molecular Hepatology.2026; 32(1): 407.     CrossRef
  • Should direct-acting antiviral be considered for all patients with HCV-related hepatocellular carcinoma?: Reply to correspondence on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
    Yan Ling Ong, Apichat Kaewdech, Yu Jun Wong
    Clinical and Molecular Hepatology.2026; 32(1): e109.     CrossRef
  • Acute Changes in Liver and Spleen Stiffness Following Endoscopic Variceal Ligation in Advanced Liver Disease—A Pilot Study
    Esra Görgülü, Eva Herrmann, Jonel Trebicka, Alexander Queck, Georg Dultz, Vitali Koch, Stefan Zeuzem, Jörg Bojunga, Viola Knop, Florian Alexander Michael, Mireen Friedrich Rust
    Journal of Clinical Medicine.2026; 15(2): 816.     CrossRef
  • Prognostic Impact of Varices and Hemorrhagic Events in Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab
    Jeayeon Park, Dong Ho Lee, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon, Su Jong Yu
    Gut and Liver.2026; 20(2): 315.     CrossRef
  • Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review
    Audrey Payancé, Pierre‐Emmanuel Rautou, Jérôme Boursier, Laurent Castera, Dominique Valla, Laure Elkrief
    Liver International.2026;[Epub]     CrossRef
  • Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI‐2D‐SWE‐Based Liver Stiffness Measurement
    Christian Sebesta, Georg Kramer, Nina Dominik, Benedikt S. Hofer, Lorenz Balcar, Paul Thöne, Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Till Schöchtner, Friedrich Haimberger, Nicolas Balutsch, Albert F. Stättermayer, Michael Trauner, Mattias Mandorf
    Liver International.2026;[Epub]     CrossRef
  • Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis
    Jarell Jie-Rae Tan, Ellina Lytvyak, Joo Wei Ethan Quek, Corrine Lee Singh, Yuan Jie Aidan Low, Shi Jie Ong, Mark Muthiah, Yu Jun Wong, Aldo J. Montano-Loza
    Hepatology Communications.2026;[Epub]     CrossRef
  • Predicting the Risk of Decompensation in Patients With Cirrhosis: A Validated Machine Learning Approach
    Philip J. Johnson, Anton Kalyuzhnyy, Arturas Grauslys, Hidenori Toyoda, Erica Villa, Omar Elshaarawy, Stephen Stewart, Ian A. Rowe, Jessica Shearer, Indra Neil Guha
    American Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis: A Clinical Review
    Jan Christoph Schumacher, Joshua Leutiger, Anna Martin, Münevver Demir, Christoph Neumann-Haefelin, Philipp Kasper
    Biomedicines.2026; 14(5): 1133.     CrossRef
  • Noninvasive Prediction of Decompensation in Compensated Advanced Chronic Liver Disease and a Liver Stiffness From 15 to 25 kPa
    Angus W. Jeffrey, Avik Majumdar, Gary P. Jeffrey, Michael C. Wallace, Tim Mitchell, Stuart K. Roberts, Kiran Rasaratnam, Leon A. Adams
    Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • Steatotic liver disease in autoimmune liver disease: Prevalence and clinical impact in a Southeast Asian cohort
    Jarell Jie-Rae Tan, Shwetha Thiyagarajan, Jessica Tan, Jeannie Ong, Kenneth Lin, Chin-Hock Nicholas Tee, Chin Kimg Tan, Andrew Tan, Daphne Ang, Tiing Leong Ang, Andrew Kwek, Yu Jun Wong
    Canadian Liver Journal.2026; 9(3): 432.     CrossRef
  • Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease
    Jarell Jie‐Rae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, Ming‐Hua Zheng, Christophe Corpechot, Aldo J. Montano‐Loza, Yu Jun Wong
    Liver International.2026;[Epub]     CrossRef
  • Future directions in noninvasive prediction of cirrhosis decompensation: An opinion review
    Xin Gao, Dan-Yang Zhang, Yan Wang
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Shear Wave Elastography Combined with ALBI Score Enhances Prediction of Hepatic Decompensation in Chronic Liver Disease
    Jaejun Lee, Hyun Yang, Si Hyun Bae, Sun Hong Yoo, Soon Woo Nam, Jiwoon Yoon, Jung Hyun Kwon, Soon Kyu Lee
    JHEP Reports.2026; : 101963.     CrossRef
  • Biochemical Response in Asian PBC: A Strong Signal, but Not the Whole Story
    Jeanette Pei Xuan NG, Jarell TAN, Yu Jun WONG
    Journal of Clinical and Experimental Hepatology.2026; : 103647.     CrossRef
  • Acute and non‐acute decompensation of liver cirrhosis
    Martin S. McCoy, Paolo Angeli, Jonel Trebicka
    Liver International.2025;[Epub]     CrossRef
  • Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients
    Yu Jun Wong, Vincent L. Chen, Asim Abdulhamid, Giulia Tosetti, Huttakan Navadurong, Apichat Kaewdech, Jessica Cristiu, Michael Song, Pooja Devan, Kai Le Ashley Tiong, Jean Ee Neo, Thaninee Prasoppokakorn, Pimsiri Sripongpun, Catherine Ann Malcolm Stedman,
    Hepatology.2025; 81(2): 523.     CrossRef
  • Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial
    Elton Dajti, Càndid Villanueva, Annalisa Berzigotti, Anna Brujats, Agustín Albillos, Joan Genescà, Juan C. García-Pagán, Antonio Colecchia, Jaume Bosch, Càndid Villanueva, Agustín Albillos, Joan Genescà, Juan C. Garcia-Pagan, José L. Calleja, Carles Araci
    Journal of Hepatology.2025; 82(3): 490.     CrossRef
  • Non-invasive assessment of portal hypertension: Liver stiffness and beyond
    Mattias Mandorfer, Juan G. Abraldes, Annalisa Berzigotti
    JHEP Reports.2025; 7(3): 101300.     CrossRef
  • Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
    Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing
    Clinical and Molecular Hepatology.2025; 31(1): 105.     CrossRef
  • Preventing the progression of cirrhosis to decompensation and death
    Càndid Villanueva, Dhiraj Tripathi, Jaume Bosch
    Nature Reviews Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
    Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2025; 31(Suppl): S51.     CrossRef
  • A systematic review of noninvasive laboratory indices and elastography to predict hepatic decompensation
    John Grady, Michael Song, Whitney Townsend, Nadim Mahmud, Elliot B. Tapper, Neehar D. Parikh
    Hepatology Communications.2025;[Epub]     CrossRef
  • EASL postgraduate course report: Vascular biology in chronic liver disease and clinical management implications
    Pierre-Emmanuel Rautou, Ton Lisman, Virginia Hernandez-Gea, Cristina Ripoll
    JHEP Reports.2025; 7(8): 101399.     CrossRef
  • Current and new strategies for hepatocellular carcinoma surveillance
    Natchaya Polpichai, Chongkonrat Maneenil, Pojsakorn Danpanichkul, Chitchai Rattananukrom, Ashok Choudhury, Yu Jun Wong, Pimsiri Sripongpun, Suthat Liangpunsakul, Apichat Kaewdech
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
    Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755.     CrossRef
  • Advances in the diagnosis and management of clinically significant portal hypertension in cirrhosis: A narrative review
    Xiao-Yu Xie, Amine Benmassaoud
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis
    Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin
    Clinical and Molecular Hepatology.2025; 31(3): 866.     CrossRef
  • The Impact of Esophagogastric Varices on the Outcomes of Patients With Cholangiocarcinoma
    Tzu-Han Ma, Yu-Jen Chen, Chun-Ting Ho, Pei-Chang Lee, Tsung-Chieh Yang, Hui-Chun Huang, Yi-Hsiang Huang, Ming-Huan Chen, Jiing-Chyuan Luo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
    Clinical and Translational Gastroenterology.2025; 16(12): e00930.     CrossRef
  • Adding 100 Hz Spleen Stiffness Measurement to the Baveno VII Model Improves Decompensation Risk Prediction in cACLD
    Emma Vanderschueren, Wim Laleman
    Liver International.2025;[Epub]     CrossRef
  • Disease-specific non-invasive assessment of liver fibrosis and portal hypertension
    Tancredi V. LI CAVOLI, Armando CURTO, Erica N. LYNCH, Andrea GALLI, Stefano MILANI
    Minerva Gastroenterology.2025;[Epub]     CrossRef
  • Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events
    Yameng Sun, Wei Chen, Shuyan Chen, Xiaoning Wu, Xinxin Zhang, Lingyi Zhang, Hong Zhao, Mingyi Xu, Yongpeng Chen, Hongxin Piao, Ping Li, Lei Li, Wei Jiang, Xiaodong Li, Huichun Xing, Xudong Liu, Yuxi Zhang, Bingqiong Wang, Jialing Zhou, Tongtong Meng, Xiny
    Clinical Gastroenterology and Hepatology.2024; 22(3): 591.     CrossRef
  • Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient
    Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Georg Semmler, Lorenz Balcar, Benedikt Silvester Hofer, Michael Schwarz, David Bauer, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Thomas Reiberger, Mattias Mandorfer
    Journal of Hepatology.2024; 80(5): 744.     CrossRef
  • Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients
    Dmitry Victorovich Garbuzenko
    World Journal of Hepatology.2024; 16(2): 126.     CrossRef
  • Role of Vibration-Controlled Transient Elastography in the Evaluation and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Elizabeth E. Williams, Raj Vuppalanchi
    Current Hepatology Reports.2024; 23(3): 355.     CrossRef
  • Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial
    Vishal C. Patel, Mark J. McPhail, Ruhama Uddin, Hassan Jafari, Vanessa Lawrence, Clair Le Boutillier, James Shearer, Nahel Yaziji, Angela Cape, Haroon Ahmed, Christopher Ward, Peter Walsh, Kevin Besly, Ane Zamalloa, Joanna Kelly, Ashis Mukhopadhya, Alicij
    Trials.2024;[Epub]     CrossRef
  • Clinical Management practice and Therapeutic Outcomes of Chronic Liver Disease patients in the Conflicted area of North Ethiopia
    Hawaz Shewatetak, Raghavendra Yarlagadda, Kotaiah Silakabattini, Ramanji Reddy Tatiparthi, Venkateswara Rao Jallepalli
    Research Journal of Pharmacy and Technology.2024; : 1267.     CrossRef
  • Pharmacologic Treatment of Portal Hypertension
    Yu Jun Wong, Juan G. Abraldes
    Clinics in Liver Disease.2024; 28(3): 417.     CrossRef
  • Noninvasive Assessment of Portal Hypertension
    Juan Bañares, Laia Aceituno, Mònica Pons, Joan Genescà
    Clinics in Liver Disease.2024; 28(3): 401.     CrossRef
  • Screening for exclusion of high-risk bleeding features of esophageal varices in cirrhosis through CT and MRI
    Ali Borhani, Harry Luu, Alireza Mohseni, Ziyi Xu, Mohammadreza Shaghaghi, Celestina Tolosa, Mohammad Mirza Aghazadeh Attari, Seyedeh Panid Madani, Haneyeh Shahbazian, Pegah Khoshpouri, Shadi Afyouni, Ghazal Zandieh, Ihab R. Kamel, Amy K. Kim
    Clinical Imaging.2024; 110: 110168.     CrossRef
  • Performance of Baveno VII criteria for the screening of varices needing treatment in patients with biliary atresia
    Yu‐Chieh Ling, Chien‐Ting Hsu, Cheng‐Yu Chen, Chi‐San Tai, Kai‐Chi Chang, Jia‐Feng Wu
    Journal of Pediatric Gastroenterology and Nutrition.2024; 79(2): 222.     CrossRef
  • Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
    Lung-Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, Kuo Chao Yew, Nobuharu Tamaki, Ruveena Bhavani Rajaram, Mara Teresa Panlilio, Rashid Lui, Hye Won Lee, Jimmy Che-To Lai, Anand V. Kulkarni, Madhumita Premkumar, Cosmas Rinaldi Adithya Lesmana, Yao Chun Hsu,
    Nature Reviews Gastroenterology & Hepatology.2024; 21(12): 834.     CrossRef
  • Meta-analysis: accuracy of the Baveno VI criteria for the diagnosis of high-risk varices in patients with hepatocellular carcinoma
    Xiaoqin Zheng, Tingting Mei, Hui Xu, Heran Yin, Hua Jin, Chunyan Gou, Xiaojun Wang, Huiguo Ding
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Serial Liver Stiffness Measurement and Fibrosis-4 Scores in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Tanvi Goyal, Michael W. Song, Deepika Suresh, Venkata S. J. Jasty, Esteban Urias, Karn Wijarnpreecha, Yu Jun Wong, Vincent L. Chen
    Digestive Diseases and Sciences.2024; 69(11): 4250.     CrossRef
  • Examining the therapeutic landscape of beta-blockers in portal hypertension
    Anna Brujats, Càndid Villanueva
    Clinical and Molecular Hepatology.2024; 30(4): 1055.     CrossRef
  • Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort study
    Shanghao Liu, Jia Li, Yujun Wong, Hyung Joon Yim, Masashi Hirooka, Hirayuki Enomoto, Qing Xie, Erhei Dai, Amr Shaaban Hanafy, Zhujun Cao, Lili Zhao, Kok Ban Teh, Tae Hyung Kim, Young Kul Jung, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima,
    MedComm.2024;[Epub]     CrossRef
  • Contemporary concepts of prevention and treatment of gastroesophageal variceal bleeding in liver cirrhosis patients (based on the BAVENO VII consensus conference materials, October 2021)
    D. V. Garbuzenko
    Continuing Medical Education and Science.2024; 19(2): 32.     CrossRef
  • Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
    Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani
    Clinical and Molecular Hepatology.2023; 29(1): 188.     CrossRef
  • The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus
    Jeong-Ju Yoo, Sang Gyune Kim
    Clinical and Molecular Hepatology.2023; 29(1): 102.     CrossRef
  • Non-invasive tests-based risk stratification: Baveno VII and beyond
    Georg Semmler, Mathias Jachs, Mattias Mandorfer
    Clinical and Molecular Hepatology.2023; 29(1): 105.     CrossRef
  • Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey
    Susana G Rodrigues
    Clinical and Molecular Hepatology.2023; 29(1): 110.     CrossRef
  • Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(8): 1372.     CrossRef
  • Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII
    Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik, Dong Hyun Sinn
    Liver International.2023; 43(9): 1966.     CrossRef
  • Letter: Baveno‐VI criteria to exclude large varices in patients with hepatocellular carcinoma—What have we learned?
    Yu J. Wong
    Alimentary Pharmacology & Therapeutics.2023; 58(6): 642.     CrossRef
  • Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
    Luca Rinaldi, Chiara Giorgione, Andrea Mormone, Francesca Esposito, Michele Rinaldi, Massimiliano Berretta, Raffaele Marfella, Ciro Romano
    Viruses.2023; 15(8): 1730.     CrossRef
  • Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease
    Yu Jun Wong, Esteban Urias, Michael W. Song, Tanvi Goyal, Wei Xuan Tay, Nicole Xinrong Han, Jing Hong Loo, Tian Yu Qiu, Karn Wijarnpreecha, Yiong Huak Chan, Vincent L. Chen
    Hepatology Communications.2023;[Epub]     CrossRef
  • 19,277 View
  • 470 Download
  • 56 Web of Science
  • Crossref